CXCR4 receptor as a promising target for oncolytic drugs.
There has been considerable in vivo evidence that chemokine receptor CXCR4 and its endogenous ligand CXCL12 modulate some important physiological and pathophysiological processes, including cancer metastasis, angiogenesis, invasion, growth and progression. In this review we elucidate key aspects of CXCL12-CXCR4 signaling system with emphasis on peptide-based and small-molecule CXCR4 inhibitors.
Small Molecule Drug Discovery, ChemDiv, Inc., San Diego, California 92121, USA.
Yan
Y
Lavrovsky
Yan A
YA
Ivanenkov
Konstantin V
KV
Balakin
Darya A
DA
Medvedeva
Alexandre V
AV
Ivachtchenko
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D054377:Chemokine CXCL12 / Q000378:metabolism; D015195:Drug Design; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000970:Antineoplastic Agents; D054377:Chemokine CXCL12; D010455:Peptides; D019718:Receptors, CXCR4